tetano
Editor, Senior Moderator
J Med Virol
. 2023 Oct;95(10):e29179.
doi: 10.1002/jmv.29179. Characterization of B-cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS-CoV-2 infection
Evgeny Arons[SUP] 1 [/SUP], Kiersten Henry[SUP] 2 [/SUP], Christopher Haas[SUP] 3 [/SUP], Mory Gould[SUP] 1 [/SUP], Jack Tsintolas[SUP] 1 [/SUP], Jack Mauter[SUP] 1 [/SUP], Hong Zhou[SUP] 1 [/SUP], Peter D Burbelo[SUP] 4 [/SUP], Jeffrey I Cohen[SUP] 5 [/SUP], Robert J Kreitman[SUP] 1 [/SUP]
Affiliations
Although monoclonal antibodies to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are known, B-cell receptor repertoire and its change in patients during coronavirus disease-2019 (COVID-19) progression is underreported. We aimed to study this molecularly. We used immunoglobulin heavy chain (IGH) variable region (IGHV) spectratyping and next-generation sequencing of peripheral blood B-cell genomic DNA collected at multiple time points during disease evolution to study B-cell response to SARS-CoV-2 infection in 14 individuals with acute COVID-19. We found a broad distribution of responding B-cell clones. The IGH gene usage was not significantly skewed but frequencies of individual IGH genes changed repeatedly. We found predominant usage of unmutated and low mutation-loaded IGHV rearrangements characterizing naïve and extrafollicular B cells among the majority of expanded peripheral B-cell clonal lineages at most tested time points in most patients. IGH rearrangement usage showed no apparent relation to anti-SARS-CoV-2 antibody titers. Some patients demonstrated mono/oligoclonal populations carrying highly mutated IGHV rearrangements indicating antigen experience at some of the time points tested, including even before anti-SARS-CoV-2 antibodies were detected. We present evidence demonstrating that the B-cell response to SARS-CoV-2 is individual and includes different lineages of B cells at various time points during COVID-19 progression.
Keywords: BCR; COVID-19; IGH chain; IGHV rearrangement; SARS-CoV-2; antibody titer; clonality; genetic and hematological bio-indices; pandemic.
. 2023 Oct;95(10):e29179.
doi: 10.1002/jmv.29179. Characterization of B-cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS-CoV-2 infection
Evgeny Arons[SUP] 1 [/SUP], Kiersten Henry[SUP] 2 [/SUP], Christopher Haas[SUP] 3 [/SUP], Mory Gould[SUP] 1 [/SUP], Jack Tsintolas[SUP] 1 [/SUP], Jack Mauter[SUP] 1 [/SUP], Hong Zhou[SUP] 1 [/SUP], Peter D Burbelo[SUP] 4 [/SUP], Jeffrey I Cohen[SUP] 5 [/SUP], Robert J Kreitman[SUP] 1 [/SUP]
Affiliations
- PMID: 37877800
- DOI: 10.1002/jmv.29179
Although monoclonal antibodies to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are known, B-cell receptor repertoire and its change in patients during coronavirus disease-2019 (COVID-19) progression is underreported. We aimed to study this molecularly. We used immunoglobulin heavy chain (IGH) variable region (IGHV) spectratyping and next-generation sequencing of peripheral blood B-cell genomic DNA collected at multiple time points during disease evolution to study B-cell response to SARS-CoV-2 infection in 14 individuals with acute COVID-19. We found a broad distribution of responding B-cell clones. The IGH gene usage was not significantly skewed but frequencies of individual IGH genes changed repeatedly. We found predominant usage of unmutated and low mutation-loaded IGHV rearrangements characterizing naïve and extrafollicular B cells among the majority of expanded peripheral B-cell clonal lineages at most tested time points in most patients. IGH rearrangement usage showed no apparent relation to anti-SARS-CoV-2 antibody titers. Some patients demonstrated mono/oligoclonal populations carrying highly mutated IGHV rearrangements indicating antigen experience at some of the time points tested, including even before anti-SARS-CoV-2 antibodies were detected. We present evidence demonstrating that the B-cell response to SARS-CoV-2 is individual and includes different lineages of B cells at various time points during COVID-19 progression.
Keywords: BCR; COVID-19; IGH chain; IGHV rearrangement; SARS-CoV-2; antibody titer; clonality; genetic and hematological bio-indices; pandemic.